47.45 -0.13 (-0.28%)
After hours: 4:16PM EDT
|Bid||47.57 x 1000|
|Ask||47.56 x 1800|
|Day's range||47.02 - 47.62|
|52-week range||32.22 - 48.68|
|Beta (3Y monthly)||0.12|
|PE ratio (TTM)||29.85|
|Forward dividend & yield||0.72 (1.54%)|
|1y target est||52.00|
Is Smith & Nephew plc (LON:SN.) a good dividend stock? How can we tell? Dividend paying companies with growing...
Examining how Smith & Nephew plc (LON:SN.) is performing as a company requires looking at more than just a years...
Looking at Smith & Nephew plc's (LON:SN.) earnings update in December 2018, it seems that analyst forecasts are fairly...
With Smith & Nephew's (SNN) buyout of Atracsys, the latter's fusionTrack 500 optical tracking camera will be a core enabling technology for the company's next-generation robotics platform.
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
The transaction by Smith & Nephew (SNN), besides the business purchase, comprises certain intangible assets and the orthopaedic Brainlab salesforce.
Titan Medical (TMDI) is putting in a good deal of effort to strengthen its position in the multi-billion dollar computer-assisted robotic surgical technologies market.
Attractive stocks have exceptional fundamentals. In the case of Smith & Nephew plc (LON:SN.), there's is a notable dividend-paying company that has been able to sustain great financial health over t...
Today we'll look at Smith & Nephew plc (LON:SN.) and reflect on its potential as an investment. Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. F...
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are currently a shareholder in Smith & Nephew plc (LON:SN.), or considering investing in the stock, you need to examin...
The Zacks Analyst Blog Highlights: Rio Tinto, Smith & Nephew, Endava, AstraZeneca and British American Tobacco
WILMINGTON, Del., March 14, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Osiris Therapeutics, Inc. (NASDAQ GM: OSIR)? Did you purchase any of your shares prior to.